Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma

NCT03108027 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
DRUG: Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
DRUG: Treatment C: Placebo (morning dose) and placebo (evening dose)

Sponsor

Novartis Pharmaceuticals